{"id":"W2112524831","doi":"10.1200/jco.2011.39.2993","title":"Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":212,"is_retracted":false,"has_abstract":true,"ca_institutions":"Lakeridge Health","funders":"","keywords":"Erlotinib; Medicine; Sunitinib; Internal medicine; Lung cancer; Rash; Oncology; Erlotinib Hydrochloride; Hazard ratio; Clinical endpoint; Epidermal growth factor receptor; Phases of clinical research; Gastroenterology; Cancer; Chemotherapy; Clinical trial; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002212574,0.001972656,0.003666149,0.0004967923,0.000512796,0.00125338,0.0009475933,0.001723895,0.005517515],"category_scores_gemma":[0.001632382,0.0006349007,0.002809409,0.0005055313,0.0009767839,0.001196295,0.0003513592,0.003192372,0.001054677],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008249045,"about_ca_system_score_gemma":0.001214504,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005942027,"about_ca_topic_score_gemma":0.001622612,"domain_scores_codex":[0.9993854,0.0003045238,0.00005150491,0.0001231888,0.00004609365,0.00008928025],"domain_scores_gemma":[0.9991013,0.0002341998,0.0002273691,0.00005952533,0.00005210418,0.0003256396],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9715509,0.006021248,0.0006347432,0.000563149,0.001079732,0.00004733416,0.00004917995,0.0004699444,0.002169037,0.00007190213,0.0006927126,0.01665006],"study_design_scores_gemma":[0.9253427,0.07099311,0.001671263,0.0000378521,0.0004698018,0.00005457741,0.00001608245,0.0005087476,0.0003020933,0.0001223544,0.0004685078,0.00001286951],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9828692,0.008607811,0.000596709,0.0008732494,0.0007476005,0.003306276,0.0009171054,0.0001441774,0.001937839],"genre_scores_gemma":[0.9871274,0.003659501,0.000949704,0.0009397014,0.0005119989,0.003520598,0.000877182,0.00002103765,0.002392823],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005517515,"threshold_uncertainty_score":0.01845789,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07140800855381599,"score_gpt":0.4732130208390218,"score_spread":0.4018050122852058,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}